Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Differential expression of soluble cerebrospinal fluid, serum, and cell surface markers in neuromyelitis optica spectrum disorder
Multiple Sclerosis
P14 - Poster Session 14 (8:00 AM-9:00 AM)
9-007
To identify diagnostic biomarkers of neuromyelitis optica spectrum disorder (NMOSD).

NMOSD is a chronic autoimmune disease of the CN) that is associated with anti-aquaporin 4 (AQP4) autoantibodies in most patients. Neuroinflammation in NMOSD involves autoantibodies, cytokines, and B- and T-cell mediated responses. However, the mechanisms of CNS tissue damage in NMOSD have not been elucidated.

We measured relative expression of 274 soluble biomarkers from the serum of 11 untreated NMOSD patients and 11 age-, sex- and race-matched healthy controls (HCs) using protein arrays (G4000, RayBiotech). Biomarkers were also measured in the CSF of 6 NMOSD patients and 6 control subjects. All NMOSD patients tested positive for serum anti-AQP4 antibodies by the indirect immunofluorescence assay (Euroimmun AG) or the cell-based assay. Fresh peripheral blood mononuclear cells from 7 untreated NMOSD patients and 4 HC were stained for CD19+ B cell markers. 
In NMOSD, serum concentrations (fold-change in patients vs. controls, p value) of prolactin (2.9, 0.001), IL-2Rgamma (2.0 0.01), vascular endothelial growth factor (VEGF) R2 (2.2, 0.014) and VE-Cadherin (1.7, 0.05) were increased in comparison to control subjescts. In CSF, the following inflammatory markers were upregulated in NMOSD patients: IL-12p70 (2.4, 0.002), luteinizing hormone (1.5, 0.06), TNFR superfamily member 27 (XEDAR) (1.5, 0.008), FGF-9 (1.7, 013), VEGF (1.8, 0.019), Nidogen-1 (1.6, 0.021), MIP-1alpha (4.1,  0.026), bFGF (2.4, 0.034), lysosome membrane protein (LIMP)II (1.9, 0.038), MMP-10 (4.6, 0.034), IL-15R alpha (1.3, 0.041), CD80 (1.4, 0.046), GRO (2.7, 0.047), and oncostatin M (1.4, 0.049).  NMOSD patients had decreased CSF expression of MCP-1 (0.6, 0.013), ALCAM (0.5, 0.031), and Marapsin (0.5, 0.045) in comparison to HCs.  Flow cytometry study has shown that the percentage of plasmablasts was increased in NMOSD patients.
Our results provide serum and CSF differential inflammatory protein expression in patients with NMOSD which may serve as new potential diagnostic biomarkers.
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
Nazanin Kiapour, MD Dr. Kiapour has nothing to disclose.
Nazanin Kiapour, MD Dr. Kiapour has nothing to disclose.
No disclosure on file